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BACKGROUND - Cardiac ischaemic preconditioning (lPC) describes a 
biological phenomenon whereby a short ischaemic stimulus confers protection 
to the heart against subsequent prolonged ischaemia and reperfusion injury. 
Understanding this survival programme will enable us to augment tissue 
tolerance against cell death. Ischaemic preconditioning is poorly understood, 
however, certain metabolic events and activation intracellular signalling 
events are known to trigger this cardioprotection. The purpose of this study 
was to investigate the metabolic and intracellular signalling events which 
occur during ischaemic preconditioning and their effects on improvement of 
contractile recovery following an ischaemia I reperfusion insult. 
Glucose deprivation substudy - we used glucose deprivation as a trigger of 
preconditioning to compare potential metabolic changes associated with 
glucose depletion, such as decreased glycolysis and enhanced fatty acid 
mobilisation, with conventional preconditioning signalling events such as 
activation of adenosine receptor and I or adrenergic receptor activation, 
protein kinase C activation and the subsequent opening of mitochondrial ATP 
sensitive potassium (mito KATP) channels. We therefore hypothesised that, 
transient glucose depletion preconditions the heart via an induction of 
adenosine I noradrenergic activation of protein kinase C (PKC) with resultant 
opening of mito KATP channels. 
PKA inhibition substudy - Although preconditioning is cardioprotective 
against ischaemia I reperfusion injury, we proposed that the efficacy of 
ischaemic preconditioning on post ischaemic contractile function can be 
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augmented. We therefore suggested that augmentation of ischaemic 
preconditioning can be achieved by reducing the ~-adrenergic I protein kinase 
A pathway induced accumulation of Ca2 + known to occur during ischaemia. 
We therefore hypothesised that activation of cyclic AMP dependent protein 
kinase A (PKA) could mediate deleterious effects during ischaemia and may 
limit post ischaemic contractile recovery afforded by single episode of 
preconditioning. 
METHODS AND RESULTS - Isolated rat hearts were perfused with Krebs 
buffer containing 11 mM glucose prior to 30 min global ischaemia and 30 min 
reperfusion (index IIR). Ischaemic preconditioning hearts had 10 min global 
ischaemia followed by 10 min reperfusion prior to index IIR. 
Glucose deprivation substudy - Glucose deprivation preconditioned hearts 
were exposed to 15 min glucose free buffer perfusion followed by 10 min 
perfusion with glucose containing buffer prior to index I/R. Post ischaemic 
contractile recovery at the end of the experimental protocol was compared to 
the baseline and expressed as a percentage of basal contractile function. 
Ischaemic preconditioning and glucose deprivation preconditioning improved 
the functional recovery after 30 min reperfusion Control (28.5 ± 2.4 %) to 
ischaemic preconditioning (56.7 ± 3.6 %) and glucose deprivation 
preconditioning (59.8 ± 3.4 %). To evaluate the metabolic events occurring 
during the preconditioning stimulus; fatty acid mobilisation and glycolytic 
inhibition effects were investigated. This was achieved by perfusing a 
medium chain fatty acid, 11 mM octanoate, glycolytic inhibitor, 11 mM 2­
















during the glucose deprivation period. Octanoate (50.2 ± 2.5 %) and a 
combination of octanoate and 2DG (49.3 ± 3.3 %) in the absence of glucose 
were not significantly different from GLU(-) (59.8 ± 4.0 %) were all significantly 
different compared to the control (32.1 ± 4.6 %). To assess the possible 
involvement of adenosine receptor and/or adrenergic receptor activation, 
adenosine antagonist 100J..lM SPT, adrenergic antagonist prazosin (a1 blocker 
10J..lM) and propranolol (~-blocker 10J..lM) were perfused. SPT (36.7 ± 3.3 %) 
blocked GLU(-) (59.8 ± 3.4 %) protection while prazosin (50.5 ± 3.1 %) and 
propranolol (55.5 ± 4.0 %) did not block glucose deprivation protection. To 
confirm the specificity of SPT, adenosine preconditioning ADO PC (60.9 ± 6.9 
%) was abolished by SPT - ADO + SPT (28.4 ± 2.6 %). To investigate the 
role of PKC and mito KATP channel, inhibitors chelerythrine (PKC inhibitor 
10J..lM) and 5-HD (KATP channel blocker 100J..lM) were perfused prior, during 
and after glucose depletion period prior to the index ischaemia. Chelerythrine 
(35.0 ± 4.8 %) or 5-HD (23.8 ± 3.4 %) also abolished glucose deprivation 
protection. 
PKA inhibition substudy - It has been shown that the levels of cAMP decline 
with the number of ischaemia / reperfusion episodes 1, 2 hence ischaemic 
preconditioning protection improves with the number of cycles3, therefore 
protein kinase A inhibition may be due to a stronger ischaemic preconditioning 
phenomenon. We therefore compared single episode to multiple episodes of 
ischaemia and further investigated whether ~-adrenergic induced protein 















limit this cardioprotection. We therefore evaluated whether we could augment 
the cardioprotection afforded by single episode of ischaemic preconditioning 
by attenuating the activation of protein kinase A. 
Firstly, we compared the degree of improvement of post ischaemic contractile 
function with multiple cycles. Rat hearts preconditioned with single episode of 
10 min global ischaemia improved post ischaemic contractile function, IPC 1 
(45.0 ± 3.2 %) at the end of 30 min reperfusion. Moreover, rat hearts 
preconditioned with 3 x 5 min episodes of ischaemia, interspersed with 5 min 
reperfusion (IPC 3), showed significant improvement of post ischaemic 
contractile function, above that of single episode of ischaemic preconditioning, 
IPC 3 (62.8 ± 2.9 %). Prior to evaluating the role of protein kinase A 
activation on preconditioning its upstream mediator adenylate cyclase was 
activated. Hearts were pharmacologically preconditioned with the adenylate 
cyclase activator, forskolin 0.3JlM (forskolin preconditioning). Forskolin used 
as a preconditioning mimetic showed a similar protection to ischaemic 
preconditioning, (forskolin preconditioning - 35.4 ± 0.9 % versus IPC 1 - 45 ± 
3.2 %, NS). To investigate the role of protein kinase A activation during 
forskolin preconditioning stimulus, forskolin was concurrently perfused with 
protein kinase A inhibitor (2JlM H89). H89 augmented forskolin 
preconditioning (forskolin preconditioning - 35.4 ± 0.9 % versus forskolin 
preconditioning + H89 - 50.9 ± 3.9 %). H89 was then perfused prior to trigger 
ischaemia of preconditioning. Again, H89 augmented the post ischaemic 
contractile function afforded by ischaemic preconditioning alone (IPC 1 - 45 ± 
3.2 % versus IPC 1 + H89 - 58.0 ± 2.8 %, p < 0.05 vs. IPC 1). In collaboration 












during the trigger ischaemia. In correlation with the above findings, we found 
that protein kinase A activity was significantly increased at the end of 10 min 
trigger ischaemia (baseline 1739 ± 190 pmol. min-1. mg protein-1 vs 10 min 
trigger ischaemia 3055 ± 255 pmol. min-1• mg protein-1, p<0.001). In H89 
treated hearts protein kinase A activity was unaffected by 3 min H89 perfusion 
before trigger ischaemia (1440 ± 130 pmol. min-1. mg protein-1 vs baseline, 
NS). Moreover, H89 blocked the rise PKA activity following the end of 10 min 
trigger ischaemia (1120 ± 71 pmol. min-1• mg protein-1 vs baseline, NS). 
CONCLUSION - Transient glucose deprivation preconditions the heart 
through adenosine receptor induced protein kinase C activation and 
mitochondrial KATP channel opening. However, protein kinase C activation 
during GLU(-) is not mediated via U1 I p-adrenergic receptor activation. In 
addition, inhibition of protein kinase A activity further enhances the protective 
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Reduced blood flow to the heart results in a reduction in oxygen and fuel 
substrate supply to the contractile high energy consuming myocardial tissue. 
This series of events is known as myocardial ischaemia. The damaging 
metabolic and functional consequences of myocardial ischaemia can lead to 
ischaemic heart disease (IHD) which induces cardiocytes cellular dysfunction 
(stunning I hibernation) or heart muscle cell death (myocardial infarction) and 
can lead to the development of ischaemic cardiomyopathy (heart failure)4. 
The spectrum of aetiologies resulting in ischaemic heart disease 
includes thrombus within the vessels, atherosclerotic plaque forming in the 
vessel wall and spasm of the coronary artery5. Ischaemic heart disease 
manifests as four clinical syndromes namely: angina pectoris, acute 
myocardial infarction (AMI), heart failure and sudden ischaemic cardiac death 
(SICD)5. Understanding the pathophysiology of these syndromes is crucial 
for preventative and therapeutic interventions for ischaemic heart disease. 
Although there may be ethnic and gender variabilities in the prevalence of 
ischaemic heart disease there are common risk factors that need to be taken 
into consideration. The risk factors can be divided into non modifiable and 
modifiable risk factors. The nonmodifiable risk factors include age, gender, 
and weight at birth, genetic predisposition and the penetrance of genetic 
defects. The modifiable risk factors include cholesterol levels, cigarette 
smoking, hypertension and diabetes and to a lesser extent fibrinogen level, 
stress and obesity5. 
As a practical consequence of the high incidence, prevalence, morbidity and 













been developed in an attempt to decrease the adverse consequences of 
ischaemic heart disease. These include treatment that maintain oxygen 
supply by thrombolysis or mechanical opening of the artery by percutaneous 
transluminal-coronary angioplasty (PTCA) or coronary artery bypass 
grafting5. Another approach has been by reducing the energy demand of the 
heart e.g. by using beta blocking agents to lower the heart rate and reduce 
cardiac contraction4. 
An alternative approach would be to modify the cardiac cellular 
response to ischaemia thereby enabling the cardiac tissue to be more 
resistant I tolerant to ischaemic stress. In this regard, paradoxically, it has 
been found that short/transient episode(s) of ischaemia protect(s) against 
subsequent ischaemic insult. This biological phenomenon is termed 
ischaemic preconditioning (IPC)6-8 and is currently regarded as one of the 
most powerful protectors of the heart. Of note, ischaemia has various 
individual components including low oxygen (hypoxia) and lack of cardiac fuel 
substrate, glucose, to mention but a few. Interestingly, as individual triggers 
these components of ischaemia have been shown to induce cardioprotection 
against ischaemia I reperfusion injIJry9, 10. Moreover, this ischaemic 
preconditioning phenomenon has been demonstrated in multiple tissue types 
including heart, skeletal muscle, brain, liver and kidney, and in numerous 
mammalian species6-8 including human 11. These observations suggest that 
preconditioning may be an evolutionary conserved cell survival programme, 
enabling many tissue types to have an augmented tolerance to ischaemic 
insults. Thus, understanding preconditioning may have widespread clinical 













myocardial infarction, stroke or multiple-organ failure following haemodynamic 
shock. 
1.1 Cardiac Ischaemic Preconditioning 
Two types of ischaemic preconditioning have been described. These include 
classic ischaemic preconditioning whereby an initial preconditioning insult 
results in enhanced tolerance against prolonged ischaemia. This protection 
lasts for 1-2 hours following the preconditioning stimulus12, 13. The delayed 
preconditioning phenomenon or second window of protection (SWOP) is 
where an initial preconditioning insult results in enhanced tolerance against 
prolonged ischaemia 24-72 hrs following the IPC insult I stimulus14, 15, In 
our study we have concentrated on the metabolic and signalling pathways 
during preconditioning insult. 
To date, several endpoints of ischaemic preconditioning have been used in 
both classic preconditioning and SWOP but the classic end point is the delay 
of lethal damage by reducing infarct size 16. Preconditioning has also been 
shown to attenuate the incidence of reperfusion induced arrhythmias 17, and 
to induce protection against post ischaemic contractile dysfunction with· 














1.2 Triggers, ligands and cell surface receptors of classic 
ischaemic preconditioning 
The precise and elementary mechanisms underlying ischaemic 
preconditioning induced cardioprotection are currently under active 
investigation. To understand the mechanisms of preconditioning various 
individual components of ischaemia including hypoxia9, mild increase in 
calcium 19 and deprivation of a major cardiac fuel substrate, glucose 10, have 
been investigated as the possible triggers in the preconditioning signalling 
cascade. As previously mentioned, all of these components of ischaemia 
induce ischaemic preconditioning like cardioprotection. Additionally, triggers 
known to be released during trigger ischaemia of preconditioning can 
independently induce cardioprotection. These triggers include adenosine20 
acetylcholine21 , bradykinin 10, noradrenaline22, angiotensin 1123, 
endothelin24 and opioids25. The significance of these ischaemic 
preconditioning triggers appears to be species dependent. Adenosine 
appears to be more important in rabbit20, dog26 and pig25 while 
noradrenaline seems important in rats22, however, other investigators have 
shown that adenosine plays an important role in the rat heart27, 28. Most 
ischaemic preconditioning triggers act on pertussis toxin sensitive inhibitory 












1.3 Post receptor signalling following ischaemic 
preconditioning 
The stimulation of these G-protein coupled receptors, described above, lead 
to activation of either G stimulatory I inhibitory proteins. As an example, 
noradrenaline activates both a. and ~ - adrenergic cell membrane receptors, 
with a. receptor activation initiating the G inhibitory protein signalling pathway 
and ~ - receptor activation initiating G stimulatory signalling pathway. 
The a. - adrenergic, adenosine and opioids, to mention but a few, cell 
membrane receptors are GI - protein coupled, and activate phospholipase C 
(PLC). Activated PLC converts phosphatidylinositol 4,5-biphosphate (PIP2) 
into inositol 1.4,5, -triphosphate (IP3) and 1,2-diacyglycerol (DAG). The latter 
facilitates the translocation of protein kinase C (PKC) from the cytosol to 
sarcolemma29. The active .PKC may phosphorylate the opening of the 
sarcolemmal and mitochondrial (KATP) channels30,31 and activates other 
kinases like tyrosine kinase and MAP kinases15. The protein kinase C 
inhibitors or antagonists like chelerythrine have been shown to block 
protection afforded by ischaemic preconditioning therefore suggesting the 
importance of protein kinase C in the opening of these channels29. Protein 
kinase C agonists like phorbol myristate acetate or a diacylglycerol analogue 
were also shown to mimic ischaemic preconditioning32. Moreover, different 
isoforms of protein kinase C are involved in preconditioning 
cardioprotection 19, 30. Recently, transgenic mice overexpressing PKC ~ 
















On the other hand, the ~ - adrenergic cell membrane receptors are coupled to 
G-stimulatory protein in order to activate adenyl ate cyclase. This activation 
leads to rise in the cyclic AMP (cAMP) which in turn activates cAMP 
dependent protein kinase (PKA), resulting in the opening of L-type calcium 
channels, and eventually bringing about an increase in the cytosolic calcium. 
The trigger ischaemia of preconditioning is associated with the rise in cAMP 
with a concomitant increase in PKA activity2, 34 leading to increase in Ca2 + 
influx4. 
1.4 The possible end effector of preconditioning 
Mitochondrial A TP sensitive potassium channels 
The activation of PKC and the resultant opening of the KATP channels has 
been considered as a likely end-effector of preconditioning. The 
consequences of mitochondrial ATP sensitive potassium (mito KATP) channel 
opening have been proposed to include mitochondrial swelling, membrane 
depolarisation, perturbation in ATP synthesis and in mitochondrial 
respiration35, 36. Interestingly, mitochondrial swelling is known to augment 
ATP production37 and this may, in turn, be an adaptive mitochondrial 
response to cellular stress. Thus, these data suggesting that ischaemic 
preconditioning induced cellular resistance to ischaemia may be via the 
modulation of mitochondrial homeostasis. Moreover, it has been found that 
pharmacological agents that block the opening of mito KATP channels block 
ischaemic preconditioning38 and pharmacological agents that open these 
channels likewise mimic ischaemic preconditioning39. 
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Sarcolemmal ATP sensitive potassium channels 
Although the involvement of mito KATP channels has been extensively studied 
in the context of preconditioning, the role of sarcolemmal ATP sensitive 
potassium channel (sarc K ATP channels) in preconditioning remains unclear. 
Ya040 suggested that sarc KATP channels are also involved in preconditioning 
protection. The consequences of the opening of sarc KATP channels have 
been suggested to be preservation of ATP, shortening phase 3 of the action 
potential and membrane hyperpolarisation leading to decreased calcium entry 
during ischaemia and subsequent cell survival35. Some investigators have 
shown that sarc KATP channel opening reduces infarct size following 
ischaemia I reperfusion insult40-42. However, some investigators have shown 
that a selective sarcolemmal channel blockers, HMR 1883 or HMR 1098, 
































2. OBJECTIVES AND HYPOTHESES 
Multiple therapeutic approaches have been developed in an attempt to 
decrease the adverse consequences of ischaemic heart disease. Moreover, 
ischaemic preconditioning (IPC)6-8 is a biological phenomenon currently 
regarded the most powerful protector of the heart against ischaemic injury. 
However, the mechanism through which ischaemic preconditioning protects 
the heart is not clearly understood. As previously mentioned, ischaemia has 
various components e.g. hypoxia and glucose deprivation. As individual 
triggers these components can induce cardioprotection, therefore intensive 
investigation on how each of these components protect may lead to a much 
clearer understanding of ischaemic preconditioning. Of these components of 
ischaemia we decided to investigate the mechanism of glucose deprivation 
protection. We chose transient glucose deprivation as a preconditioning 
stimulus because it has been shown to protect against ischaemic injury, has 
not been extensively studied and it was considered as less severe 
preconditioning stimulus compared to ischaemic preconditioning. 
2. 1 Ischaemic preconditioning versus glucose deprivation preconditioning 
These preconditioning stimuli are both known to elicit a powerful 
cardioprotection against ischaemia I reperfusion injury and they are both 
without glucose supply. However, ischaemic preconditioning has zero 
coronary flow, no oxygen supply, no cardiac function and cannot be directly 
stimulated or inhibited during preconditioning stimulus. As opposed to 
ischaemic preconditioning, glucose deprivation period has full coronary flow, 
normal oxygen supply, maintains cardiac function and can be directly 
18 











stimulated or inhibited before, during and after preconditioning stimulus. We 
were therefore in a better position to explore and investigate the mechanisms 
of glucose deprivation protection concerning contractile recovery following an 
ischaemic insult. 
Of note, all the preconditioning triggers / stimuli are proposed to set in 
motion both metabolic events (decrease glycolysis and enhancement of fatty 
acid mobilisation) and cell signalling pathways (activation of adenosine and / 
or adrenergic receptors, protein kinase C activation and opening of ATP 
sensitive mitochondrial channels). 
Thus the purposes of this section of our study was to compare and delineate 
potential metabolic changes with conventional preconditioning signalling 
events in the context of simulated ischaemia / reperfusion, 
2.2 Delineation of metabolic and signalling pathways activated by glucose 
deprivation trigger ofpreconditioning 
The exact mechanism through which glucose deprivation induces 
cardioprotection is unclear10, 46. As shown by Goto10 the transient 
deprivation of glucose from the medium mimics ischaemic preconditioning. In 
this study we further investigate this phenomenon. The first objective of this 
study is to compare and delineate the mechanisms whereby transient 
deprivation of a major cardiac fuel substrate - glucose, can induce 
cardioprotection. It was hypothesised that transient glucose deprivation may 
induce the cardiac preconditioning programme either, by direct metabolic 
effects including inhibition of glycolysis and/or enhancement of fatty acid 
mobilisation / metabolism or, by directly mimicking classic ischaemic 
19 
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preconditioning signalling pathways through the activation of PKC and 
mitochondrial KATP channel opening. 
2.3 Is there a room for further protection ofpreconditioned hearts? 
Although ischaemic preconditioning is regarded as most powerful protector of 
the heart against ischaemia I reperfusion injury, the post-ischaemic contractile 
function of the hearts subjected to a preconditioning stimulus does not revert 
completely back to pre-stimulus or baseline status following the index 
ischaemic insult. 
One of many ways in which ischaemia can damage the heart is activation of 
PKA signalling pathway and subsequent accumulation of calcium. Within a 
short period of ischaemia, endogenous catecholamines47 and noradrenaline 
release48 lead to activation the p-adrenergic receptors, adenylate cyclase 
activation, rise in cAMP levels, activation of protein kinase A and Ca2 + 
accumulation. Excess accumulation of Ca2 + in acute myocardial ischaemia 
may lead to loss of Ca2 + handling and failing of Ca2 + ATPase leading to loss of 
Ca2+ responsiveness by contractile proteins Le. actin and myosin49, 
degradation of myofilament proteins, especially Troponin 150. McDonald51 
found that excess Ca2 + can result to decreased Ca2 + sensitivity of isometric 
tension and rate of crossbridge cycling in skinned myocytes isolated from pig 
myocardium. All this may account for the contractile dysfunction observed at 
reperfusion. We therefore hypotheSised that activation of the p-adrenergic 
induced activation of cyclic AMP dependent protein kinase A (PKA) during the 
trigger of ischaemic preconditioning may limit this protection. Therefore, the 















contractile recovery can be further enhanced with the concurrent inhibition of 
the signalling pathway resulting in the augmentation of intracellular Ca2+ 
accumulation. If this could be achieved, we proposed that it could be possible 
to further enhance the protection afforded by the preconditioning stimulus. 
Although we hypothesised that ischaemic preconditioning induced protection 
can be further augmented by blocking the PKA activation, it is important to 
mention that ~-adrenergic Signalling cascade is an essential trigger of 
ischaemic preconditioning since ~-adrenergic blockade abolishes protective 
effect of preconditioning2. 
To test these hypotheses: 
1) 	 Firstly, we induced potential metabolic changes by inhibiting glycolysis 
with glycolytic inhibitor, 2-Deoxyglucose and a metabolic substrate known 
to . indirectly inhibit glycolysis, pyruvate and enhancing fatty acid 
metabolism/mobilisation and indirectly inhibiting glycolysis with a medium 
chain fatty acid, octanoate. We also blocked the conventional 
preconditioning signalling events (activation of alpha and bela-adrenergic 
receptors, adenosine receptors, PKC and opening of KATP channels) with 
various pharmacological agents. 
2) Secondly, we investigated a possible detrimental component of ischaemia 



























3. MATERIALS AND METHODS· 
In order to investigate the effects of glucose deprivation induced signalling 
and the effect of ~-adrenergic pathway blockade on ischaemic 
preconditioning, we evaluated contractile recovery in isolated Langendorff 
perfused rat hearts following preconditioning triggers, global simulated 
ischaemia and reperfusion. The Langendorff perfusion apparatus is as shown 
in figure 1(a). In this study, the improvement of post ischaemic contractile 
function was used as a marker of cardioprotection. Figure 1 (b), a typical 
pressure trace obtained from our pilot studies, shows how would hearts 
perform when subjected to either ischaemia I reperfusion control (upper 
panel) compared to preconditioning ischaemia treatment (lower panel). 
Control hearts were subjected to a period of stabilisation followed by 
prolonged period of ischaemia, which they lost function, and reperfusion, in 
which they gained function. The value obtained at the end of the experiment 
was measured and compared to the baseline (value before any interruptions) 
and expressed as the percentage of baseline. The preconditioned hearts 
were subjected to 10 min of ischaemia followed by 10 min of reperfusion 
before being subjected to prolonged ischaemia and reperfusion. In 
comparison, the developed pressure in the ischaemic preconditioning group 
was significantly greater than that achieved by the control hearts at the end of 




























Figure 1(a) Schematic representation of Langendorff perfusion apparatus. The apparatus has two chambers, one with normal glucose 
containing perfusion medium GLU{+) and glucose deprived perfusion medium GLU(-). The perfusion medium was gassed with carbogen (95% 
02 +5% C02). Isolated rat hearts were mounted to the apparatus via the aorta and a water filled balloon was inserted into the left ventricle. The 
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Figure 1(b) A typical pressure trace from the chart recorder. The top panel represents control pressure trace, after a period of 
uninterrupted perfusion (stabilisation) hearts were subjected to 30 min ischaemia, resulting in an initial period of zero developed 
pressure followed by the late onset of ischaemic contracture. Ischaemia was followed by re-establishment of the perfusion flow 
through the heart (reperfusion) and a marked reduction in the left ventricular developed pressure (LVDP) compared to stabilisation 
phase was observed. In ischaemic preconditioning (bottom panel) hearts were subjected to stabilisation phase(S) followed by 10 min 
ischaemia(IPC) I reperfusion(R) before subjected to 30 min ischaemia I reperfusion insult. IPC hearts had an early onset of 




























3.1 Isolated rat heart perfusion 
All experiments were conducted on adult male Long-Evans rats weighing 250­
300g. All animals were fed ad libitum and cared for according to the "Guide 
for the Care and Use of Laboratory animals" published by the US National 
Institutes of Health (NIH publication no. 85-23, revised 1996). Rats were 
intraperitoneally anaesthetised with 0.35ml sodium pentorbabitone and then 
intravenously heparinised (200 IU) through the exposed femoral artery. The 
hearts were then rapidly excised, immersed in 4°C Krebs solution and 
mounted onto aortic cannula. Hearts were retrogradely perfused at a 
constant pressure (100cm H20) and temperature (37°C) with a modified 
Krebs-Henseleit buffer containing (mM) NaCI 118.5, NaHC03 25, KCI 4.75, 
MgS04 1.19, KH2P04 1.18, CaCI2 1.36 and glucose 11. Oxygenation of the 
perfusion medium with 95%02 and 5%C02 resulted in PC02 of approx. 40 
mmHg, P02 of approx. 550 mmHg and pH 7.4. A compliant balloon was 
inserted into the left ventricle to measure left ventricular end diastolic, systolic 
pressure, heart rate and coronary flow. These functional parameters were 
recorded throughout the experiment using a computerised bridge 
amplifier/digitizer (P~werLab / 400, AD Instruments, Sydney, Australia), and 
continuously recorded using a Windows 95 operating system and PowerLab 
software. The criteria used for the exclusion of perfused rat hearts was a heart 
rate outside 260-410 beats/min, systoliC pressure outside 70-120 mmHg, left 
I 
ventricular end diastolic pressure of 4-10 mmHg and a rate pressure product 
outside 21.000-36.000 (mmHg beats/min) x 10-3. Additionally, only hearts 


















The formula below was used to calculate the rate pressure product (RPP) : 
Rate pressure product: 
i = Heart rate x (systolic pressure - diastolic pressure) I 
1000 






RPP =(beats/min x mmHg) x 10-3 




• Heart function is the heart rate multiplied by developed pressure. 












3.1.1. Experimenta, Protocols 
As a pilot study. to evaluate whether we could induce preconditioning via 
transient glucose deprivation (metabolic inhibition) we performed the following 
I 
experimental protocols, figure 2. 
In short, all hearts were excised into Krebs solution at 4°C and retrogradely 
: 
perfused within 1 min of excision 52. After stabilisation period, Control hearts 
(CO NT) were subjected to 30 min global normothermic ischaemia and 30 min 
i 
reperfusion (index !/R). During ischaemia hearts were immersed in an 
ungassed Krebs buffer solution at 37°C and myocardial temperature 
monitored by a thermocouple indicator probe inserted into the pulmonary 
I 
artery. Ischaemic Preconditioning (IPC), after stabilisation rat hearts were 
subjected to 10 min. global normothermic ischaemia and 10 min reperfusion 
prior to index IIR. 
Glucose deprivation preconditioning GLU(-). hearts were exposed to 15 
min glucose free buffer perfusion followed by 10 min reperfusion with glucose 
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70' 1000' 15' 30' 40' 
Figure 2: Experimental protocols depicting the timing of each intervention in 

isolated Langendorff perfused rat hearts. The white blocks represent normal 

aerobic perfusion, the hatched blocks represent global normothermic 

ischaemia and the black block represents 15 min glucose deprivation period. 
















Glucose Deprivation Preconditioning and Cellular Metabolic 
Interventions 
The potential alternate metabolic substrate hypothesis is discussed and 
illustrated in figure 3(a}. In brief, glucose deprivation is a metabolic stress that 
may result in enhanced fatty acid mobilisation / metabolism and / or result in 
reduced rate of glycolysis. Moreover, fatty acid mobilisation may, in turn, 
inhibit glycolysis53. To test whether fatty acids as an alternate substrate or a 
direct effect of glycolytic inhibition was responsible for glucose deprivation 
protection, fatty acid supplementation and glycolytic inhibition were perfused 
in the presence of glucose. To enhance fatty acid mobilisation / metabolism, 
rat hearts were supplemented with a medium chain fatty acid, octanoate, also 
known to inhibit glycolysis53. An alternative approach was to inhibit 
glycolysis with 11 mM 2-deoxyglucose (20G) an agent which is known to 
inhibit glycolysis by binding to hexokinase. The protocols used to evaluate 
this hypothesis are as shown in figure 3(b}. Rat hearts were exposed to 15 
min medium chain fatty acid, 11mM octanoate (OCT) or 11 mM 2­
deoxyglucose (20G) in the presence of glucose containing buffer followed by 
10 min washout period before being subjected to index IIR. Additionally, Goto 
et. al 10 showed that reduced glycolysis may effect glucose deprivation 
protection. To investigate this, a medium chain fatty acid, 11 mM octanoate 
{GLU(-) OCT}. or a combination of 11 mM octanoate and 11 mM 2­
deoxyglucose {GLU(-) OCT + 20G} or 20 mM pyruvate {GLU(-) PYR}, a 
metabolic substrate also known to inhibit glycolysis 54, was added during 15 
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Figure 3(a) Schematic representation of the possible metabolic pertubations in the heart following glucose deprivation. Glucose deprivation is a 
metabolic stress leading to increased fatty acid mobilization and/or glycolytic inhibition. Both fatty acid mobilization, which may lead to uncoupling 
of the oxidative phosphorylation and glycolytic inhibition can result in ATP depletion. In turn, this hypothetical dpletion of ATP may lead to the 
opening of the mitochondrial ATP sensitive potassium channels. To test whether glucose deprivation protection acts via these metabolic 
pertubations a medium chain fatty acid, octanoate was used to enhance fatty acid mobilization and to inhibit glycolysis and a glycolytic inhibitor, 
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Figure 3(b): Experimental protocols depicting the timing of each intervention 
in isolated Langendorff perfused rat hearts. The white blocks represent 
normal perfusion, hatched blocks represent global normothermic ischaemia 
and the black block represents glucose deprivation period, GLU(-). The white 
blocks with OCT or 2DG represent a period when octanoate (OCT) or 
glycolytic inhibitor (2DG) was perfused together with normal glucose 
containing for 15 min. Black block with an arrow underneath means that 
octanoate (OCT) or a combination of octanoate and 2-Deoxyglucose (OCT 
and 2DG) or pyruvate (PYR) was perfused for 15 min during glucose 
deprivation period. 












Glucose Deprivation Preconditioning and Cellular Signalling 
Interventions 
As discussed previously, some of the classic signalling events known to 
induce ischaemic preconditioning, include adenosine and a, ~ - adrenergic 
receptor signalling cascades. To investigate whether metabolic 
preconditioning is via any of these classic signalling pathways, various 
antagonists were administered, as shown in figure 4(a). The protocols are as 
shown in figure 4(b). In brief, in control hearts antagonist infusion 
commenced 10 min prior to index I/R. In GLU(-) hearts, antagonist infusion 
was commenced 5 min prior to the GLU(-) period and stopped at the 
beginning of the 30 min IIR. To block adenosine activation 100J.lM 8-SPT (a 
nonselective adenosine receptor blocker - ICso values for A1 and A2 are 4.3 
and 6.2 respectively)55 was used. a1 and ~-adrenergic receptor activation 
were blocked by the antagonists prazosin (a1-blocker-10J.lM)56, 57 and 
propranolol (~-blocker-1 OJ.lM )58 respectively. As the adenosine antagonist 
studies implicated this nucleotide as a mediator during glucose deprivation, 
we performed an additional set of experiments to confirm the speCificity of 
100J.lM SPT, adenosine receptor blocker. In these experiments we 
preconditioned with 100J.lM adenosine as PC-mimetic. After a period of 
stabilisation, adenosine was administered for 5 min followed by 10 min 
washout prior to index IIR {ADO}. To evaluate the ability of SPT to block the 
effects of adenosine preconditioning, SPT was administered 2 min prior to, 
during and after the adenosine administration until the onset of index I/R 
{ADO + SPT}. Adenosine was also administered as a pretreatment for 5 min 
prior to index I/R {Pre ADO}. To investigate the role of PKC and the KATP 
33 




















channel. inhibitors. chelerythrine (10JlM)59, 60 and 5-HD (100JlM) 30, 61 
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Figure 4(a) Schematic representation of the possible metabolic pathway through which glucose deprivation may confer protection. Glucose 
deprivation triggers the release of adenosine and activation of adenosine type 1/3 and/or noradrenaline release and activation of alpha1 and 
beta adrenergic receptors. Activation of these receptors may lead to activation of protein kinase C and subsequent opening of the mitochondrial 
ATP sensitive potassium channels. Various antagonists were used to block this pathway, namely: adenosine receptor blocker 8-(p-sulfophenyl) 
theophylline - SPT; alpha receptor blocker prazosin - PZN; beta blocker propanolol- PROP; protein kinase C inhibitor chelerythrine - CHEL; 
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Figure 4(b) Experimental protocols depicting the timing of each intervention in 
isolated Langendorff perfused rat hearts. The white blocks represent normal 
perfusion, hatched blocks represent global normothermic ischaemia and the 
black block represents glucose deprivation period, GLU(-). Arrows indicate 
the timing of pharmacological interventions. The following pharmacological 
agents were used in control and GLU(-) protocols: ADO, adenosine, SPT, 8­
(p-sulfophenyl) theophylline)-adenosine receptor blocker; PZN, prazosin-a1 
adrenergic receptor blocker and PROP, propranolol-~ adrenergic receptor 
blocker; CHEL, chelerythrine-PKC inhibitor; 5-HD, 5 hydroxydecanoate - Mito 
KATP channel blocker. Additionally, adenosine was used as PC mimetic 
(ADO) and SPT was used to block adenosine preconditioning like protection 
(ADO + SPT). In IPC group only CHEL and 5HD were used. 
D Aerobic perfusion F:-:-l Glucose deprivation period ~ Ischaemia 
~ Adenosine perfusion 
37 
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The role of protein kinase A inhibition in augmenting post ischaemic 
contractile function of single episode of preconditioning. 
It has been snown that the levels of cAMP decline with the number of 
preconditioning ischaemia I reperfusion episodes 1, 2. This increase in number 
of ischaemic preconditioning episodes correlates with much reduced infarct 
size and more improved cardioprotection compared to single episode of 
ischaemic preconditioning3. Thus, protein kinase A inhibition may be 
associated with greater ischaemic preconditioning protection. Moreover, it has 
. been shown that ischaemic preconditioning is mediated by activation of ~-
adrenergic signalling pathway. The effects of an activated protein kinase A 
signalling pathway during the trigger ischaemia of preconditioning with 
pharmacological interventions is shown in figure SA. To investigate the 
functional consequences of this correlation, we compared single episode to 
multiple episodes of ischaemia. Rat hearts were preconditioned with 3 x 5 min 
episodes of ischaemia, interspersed with 5 min reperfusion, before subjected 
to index IIR (IPC 3). To further investigate whether ~-adrenergic induced 
protein kinase A activation during Single episode of pharmacological or 
ischaemic preconditioning may limit this cardioprotection, hearts were initially 
preconditioned with an adenylate cyclase activator, 0.3J.lM forskolin. Forskolin 
was perfused as a PC mimetic for 5 min followed by a 10 min drug-free 
perfusion period before index of IIR (Forsk). In order to evaluate whether 
inhibition of PKA could further augment protection against ischaemia-induced 
contractile dysfunction, a specific PKA inhibitor, 2J.lM H89 (Ki for PKA =0.048 















PKA activity with forskolin preconditioning. H89 was perfused 3 min prior and 
during 5 min forskolin perfusion followed by a 10 min drug-free perfusion 
period before index I/R (Forsk + H89). 
To evaluate the effects of PKA inhibition with H89 against ischaemia I 
reperfusion and ischaemic preconditioning, four series of experiments were 
performed with H89. (1) H89 was perfused 3 min prior to the trigger 
ischaemia (IPC 1 + H89); (2) H89 was administered during the reperfusion 
period between preconditioning ischaemia and the index ischaemia (IPC 1 + 
H89Rep); (3) H89 was administered as a ischaemic preconditioning mimetic for 
5 min followed by 5 min washout (H89pc mimetic); (4) H89 was perfused 3 min 
• 































Figure 5 Schematic representation of P - adrenergic pathway and pharmacological interventions. Ischaemia leads to neuronal adrenaline (NA) 
release, activation of P - adrenergic receptors, activation of adenylate cyclase, amongst other things, it may lead to the rise in cAMP levels, 
activation of protein kinase A (PKA), opening of L-type calcium channels and subsequent calcium influx. Adenylate cyclase was activated by 















5' 5' 5' 
Forskpc mimetic 
Forsk + H89 
II l:l:;:~1 
8' 
IPC + H89 













20' 25 30' 












Figure 58. Experimental protocols depicting the timing of each intervention in 
isolated Langendorff perfused rat hearts. The white blocks represent normal 
perfusion, hatched blocks represent global normothermic ischaemia. Lines 
indicate H89 perfusion period. The control hearts (CONT) were subjected to a 
period of 30 min ischaemia I reperfusion (index I/R) and preconditioning 
hearts were subjected to a single episode of 10 min global ischaemia followed 
by 10 min reperFusion before subjected to index I/R (IPC 1), figure 2. In 
another set of experiments, rat hearts were preconditioned with 3 x 5 min 
episodes of ischaemia, interspersed with 5 min reperfusion, before subjected 
to index I/R (IPC 3). Forskolin was perfused for 5 min followed by 10 min drug 
free perfusion (Forsk). H89 was perfused for 3min prior to and during 5 min 
forskolin perfusion (Forsk + H89) followed by 10 min drug free perfusion 
before being subjected to index I/R. H89 was also given 3 min prior trigger 
ischaemia (IPC 1 + H89) or 10 min during reperfusion period following 10 min 
trigger ischaemia before index ischaemia (IPC 1 + H89Rep) or 5 min as 
preconditioning mimetic followed by 5 min washout (H89pc mimetic) or 3 min 
prior index ischaemia (H89Pretreatment). 














3.2 Biochemical analysis of Protein Kinase A activity 
To evaluate the degree of PKA inhibition we performed biochemical analysis 
of PKA activity with or without H89. Rat hearts were freeze-clamped at 
various time points during the experimental protocol with precooled 
Wollenberger tongs and immediately dipped into and stored in liquid nitrogen, 
Figure 5C. Tissue cAMP-dependent PKA activity was determined with an 
assay from Gibco BRL. Frozen tissue was homogenised in an extraction 
buffer (5mmoliL EDTA, 50mmoi/L Tris, pH 7.5) and centrifuged for 10 min at 
600g and the supernatant was quantitated and diluted to ± 5 J-lg protein 11 OJ-lL 
extract. Four assay conditions were used for each sample to measure the 
final percentage of activated PKA in the tissue. Two blank tubes with the 
tissue extract were set up, one with diluent and without inhibitor 1activator and 
the other without diluent but with an inhibitor and an activator. Two assay 
tubes with an extract and diluent were set up, one with an inhibitor but without 
an activator and the other with an activator but without an inhibitor. 
Duplicates of each sample were made and tubes were incubated at room 
temperature for 15 minutes to allow inhibitor to bind. To evaluate the intrinsic 
tissue PKA activity, 32P/Substrate solution was added (to each tube) and 
tubes were incubated at 30°C for 5 minutes. 20IJM was removed (from each 
tube) and spotted onto the corresponding phosphocellulose disc. The 
phosphocellulose disc sheet was immersed in a tray containing about 200ml 
• 
sulphuric acid and washed with rocking twice for 5 minutes, poured off {as 
radioactive waste. The phosphocellulose disc sheet was again washed twice 
for 5 minutes with distilled water. The phosphocellulose discs were punched 

















containing 5ml scintillation fluid. To evaluate the intrinsic tissue PKA activity, 
32p incorporation with the PKA substrate was measured on a scintillation 
counter and the results were expressed as pmol activated PKA. min-1 • mg 
protein-1• The pseudo-substrate was used as a negative control in order to 
inhibit 32p incorporation into the PKA substrate. The protein content of 
























Figure 5C Experimental protocols depicting the timing of each PKA activity 
measurement in isolated Langendorff perfused rat hearts. The white blocks 
represent normal perfusion, hatched blocks represent global normothermic 
ischaemia. The line indicates the timing of the pharmacological interventions. 
Untreated hearts were freeze-clamped at the baseline (A) and the end of 10 
min ischaemia (8). H89 treated hearts were freeze-clamped 3min after drug 
infusion (indicated by an arrow) before ischaemia (C). and at the end of 10 
min ischaemia (0). 












Forskolin hydrochloride, prazosin hydrochloride, 8-(p-sulfophenyl) 
theophylline, adenosine, chelerythrine chloride, 2-Deoxy-D-glucose, octanoic 
acid were all obtained from Sigma Chemical Corporation (St Louis, MO, USA) 
and dissolved in distilled water. 5-hydroxydecanoate was obtained from 
Research Biochemicals International (Natick, MA, USA). H89 was obtained as 
a gift from Hiroshi Hidaka, Nagoya University, Japan. Pyruvate was obtained 
from Roche molecular Biochemicals (South Africa). Chelerythrine, H89 and 
forskolin were stored as stock solutions of 200).lM, 10mM and 10-3 M at -80°C, 
respectively. All other stock solutions were made fresh daily. 
3.4 Haemodynamic parameters 
Heart rate, systolic pressure, diastolic pressure and the coronary flow were 
measured before index I/R (see tables 1-4) and at end of 30 min reperfusion 
for the glucose deprivation sub tudy and at 5min intervals until the end of 30 
min reperfusion for PKA inhibition substudy. Developed pressure was 
calculated as the difference between systolic pressure and diastolic pressure. 
Baseline heart function (heart rate X developed pressure) was measured at 
the end of stabilisation phase and compared with the values at reperfusion. 
The heart function at reperfusion was compared to and expressed as the 
percentage the baseline heart function. During ischaemia the rise in the 
diastolic pressure was considered as an ischaemic contracture. The time to 
onset of contracture (TOC), Le. the rise above the baseline diastolic pressure, 














Data was expressed as mean ± SEM. The ANOVA one - way analysis of 
variance was used to determine significance between groups in the metabolic 
studies and signalling studies. One - way ANOVA with repeated measures 
was applied in reperfusion time course and haemodynamic measures. All 
post-hoc determinations (when ANOVA showed significant differences) were 
made by the Bonferroni test for multiple comparisons. A value of P<O.05 was 
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A total of 280 rats were used for this thesis. 248 rats were used for heart 
perfusion and 32 rat hearts were freeze clamped for protein kinase A activity 
measurements. Of 248 rats used for heart perfusion, a total of 25 rats did not 
fit the exclusion criteria. We report a data on 255 rats that successfully 
completed this study. 
4.2 Transient glucose deprivation improves post ischaemic 
contractile function. 
Haemodynamic variables prior to and during ischaemia 
Ischaemic preconditioning hearts were subjected to 10 min global ischaemia 
{attenuated contractile function} and 10 min reperfusion (reversed the 
contractile function to the baseline level) prior to index ischaemia 
reperfusion. To assess whether we could induce cardioprotection by transient 
glucose deprivation, hearts were subjected to 15 min glucose deprivation 
period, an effect which depressed the cardiac function, followed by glucose 
replenishment period, which returned the cardiac contractile function to 
baseline, before subjected to index I/R, {haemodynamic parameters prior to 
index I/R and time to onset of ischaemic contracture during ischaemia are 















Baseline Post treatment Pre-ischaemia TOC 
RPP CF RPP CF RPP CF 
(10.3) (ml/min) (10.3) (ml/min) (10.3) (ml/min) (min) 
CONT 33.6±0.9 11.3 ± 0.9 33.6±0.9 11.3 ± 0.9 10.0 ± 1.3 
IPC 33.5 ± 1.5 11.7±0.8 30.1 ± 1.6 12.0 ± 1.1 4.70 ± 0.4" 
GLU(-) 31.6± 1.7 11.5 ± 0.7 17.4 ± 1.4* 8.20 ±0.9 25.8±3.7 9.30 ± 0.7 6.7 ± 0.7 
GLU{+)OCT 31.8 ±2.2 11.6 ± 0.9 29.0 ±2.0 10.4 ± 0.7 30.4 ± 1.6 10.3 ± 0.8 7.40 ± 0.9 
GLU(+)2DG 37.4 ± 1.9 13.3 ± 1.0 17.6 ± 3.6* 10.5 ± 1.5 19.5 ± 1.3* 8.20 ± 0.7 8.80 ± 0.6 
GLU(-)OCT 30.4±2.2 12.2 ± 1.3 32.0 ± 1.7 12.8 ± 1.1 26.4 ± 3.3 10.4 ± 1.8 10.8 ± 1.4 
GLU(-)OCT+2DG 34.4 ± 1.4 12.3 ± 0.6 26.9 ± 2.3 12.0 ± 1.0 26.1 ± 3.1 10.0±1.4 6.30 ± 0.5 
GLU(-)PYR 33.4 ± 0.7 14.3 ± 0.9 29.2 ±2.6 13.6 ± 0.6 23.9 ± 2.7 11.9 ± 1.2 13.0 ± 1.0 
Table 1 : Haemodynamic variables from the metabolism substudy 
Baseline - at the end of stabilisation period; RPP - rate pressure product; CF - coronary flow; Post treatment - after 15 min 
GLU(-) and/or treatment with a pharmacological agent; Pre-ischaemia - before index ischaemia; TOC time to onset of contra­
cture during ischaemia. CONT - glucose control; IPC - ischaemic preconditioning; GLU(-) - glucose preconditionining; GLU(+) 
OCT 12DG - octanoate 12-deoxyglucose in the presence of glucose; GLU(-)OCT I OCT+2DG I PYR - octanoatel a combination 
of octanoate and 2-deoxyglucose I pyruvate in the absence of glucose. 












Post ischaemic contractile recovery 
After a period of 30 min ischaemia I reperfusion, the control hearts (CONT) 
showed a significant reduction in post ischaemic contractile function 
compared to the baseline contractile function, CO NT (28.5 ± 2.8 %). 
Ischaemic preconditioning (IPC) hearts were subjected to 10 min global 
ischaemia followed by 10 min reperfusion with a subsequent return of cardiac 
contractile function to the baseline level. Ischaemic preconditioning hearts 
showed significant improvement of the post ischaemic contractile recovery, 
IPC (56.0 ± 3.6 %). Thus, as predicted, in this pilot study we found that 
transient glucose deprivation improves post ischaemic contractile function, 
GLU(-) (59.8 ± 4.0 %). We therefore concluded that glucose deprivation 
preconditioning mimics ischaemic preconditioning and improves the post 
ischaemic contractile function of the control hearts, p < 0.001 vs control, 
Figure 6. 
We therefore compared potential metabolic changes and consequences 
(decreased glycolysis and enhanced fatty acid mobilisation) with conventional 
ischaemic preconditioning signalling events (adenosine receptor and I or 
adrenergic receptor activation, protein kinase C activation and the subsequent 
opening of the ATP dependent potassium channels) as possible mechanisms 






























CONT PC GLU(-) 
TREATMENT 
Figure 6 Transient glucose deprivation preconditioning mimicks ischaemic 
preconditioning and improve post ischaemic contractile function against ischaemia I 
reperfusion insult. RPP (expressed as percentage of baseline) =rate pressure 











4.3 Glucose Deprivation Preconditioning and Cellular 
Metabolic Pathway 
Haemodynamic variables prior to and during ischaemia. 
To investigate the possible metabolic pathways that may be active during 
glucose deprivation, a medium chain fatty acid, octanoate, and an inhibitor of 
glycolysis, 2-Deoxyglucose were used as substitutes for glucose deprivation 
period, GLU(-). Replacement of GLU(-) with octanoate (OCT hearts) did not 
have any effect on cardiac function prior to the index IIR, but replacement with 
. 2-Deoxyglucose (2DG hearts) depressed the cardiac function, an effect that 
irreversibly depressed the cardiac function despite a gluc se replenishment 














Post ischaemic contractile recovery 
To study the role of fatty acid mobilisation or glycolytic inhibition we initially 
replaced 15 min glucose deprivation with octanoate or 2-deoxyglucose. The 
post ischaernic contractile recovery of octanoate, OCT (36.8 ± 3.5 %) or 2­
deoxyglucose, 2DG (34.0 ± 4.3 %) when perfused for 15 min in the presence 
of glucose did not show any significant difference to the controls, CONT (32.1 
± 4.6 %) and were all significantly reduced compared to glucose deprivation 
protection, GLU(-) (59.8 ± 4.0 %), figure7(a). 
Octanoate was then perfused in the absence of glucose (for enhancement 
fatty acid metabolism I mobilisation and consequent inhibition of glycolysis) 
and was found to be cardioprotective against ischaemia I reperfusion insult, 
GLU(-)OCT (50.2 ± 2.5 %) compared to control (32.1 ± 4.6 %), slightly lower 
but not significantly different to glucose deprivation protection GLU(-) (59.8 ± 
4.0 %). These data show that fatty acids as an alternate substrate did not 
abolish glucose deprivation mediated protection, we therefore conclude that 
glucose deprivation mediated protection does not directly act via enhanced 
fatty acid metabolism I mobilisation nor via possible octanoate-induced 
glycolytic blockade. 
To further induce glycolytic blockade a combination of octanoate and 2­
Deoxyglucose (glycolytic inhibitor) {GLU(-) OCT +2DG} was perfused in the 
absence of glucose. The use of alternate substrate (octanoate) probably 
contributed towards the maintenance of the cardiac function under these 
experimental conditions. This combination was found to be cardioprotective 
against ischaemia I reperfusion insult {GLU(-) OCT+2DG} - 49.3 ± 3.3 %. To 












deprivation protection we perfused with a different pharmacological agent 
known to indirectly inhibit glycolysis, pyruvate. Pyruvate abolished GLU(-) 
protection, GLU(-) PYR (26.6 ± 3.1 %); NS vs control, figure7(b) 
These results show that GLU(-) protection does not work via enhanced fatty 
acid metabolism and may partially act via an indirect inhibition of glycolysis by 
pyruvate. Our next step was to investigate possible cellular signalling 
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Figure 7 a The effects of enhanced fatty acid mobilization and glycolytic inhibition on 
post ischaemic contractile recovery when perfused as PC mimetic in the presence of 
glucose. 
RPP (percentage of baseline) =rate pressure product at 30 min reperfusion, n > 6 at the 




































Figure 7 b The effects of enhanced fatty acid mobilization and glycolytic inhibition on 
post ischaemic contractile function. RPP (percentage of baseline) =rate pressure 
product at 30 min reperfusion n > 6 at the end of reperfusion. All values mean ± SEM. 












4.4 Glucose Deprivation Preconditioning and Cellular 
Signalling Pathway 
Cell surface receptor blockade and glucose deprivation reconditioning. 
As previously discussed, some of the classic signalling events known to 
induce ischaemic preconditioning, include adenosine, a and ~-adrenergic cell 
surface receptor signalling cascades. To investigate whether metabolic 
preconditioning acts via any of these classic signalling pathways, adenosine, 
0.1 and ~-adrenergic receptor activation, SPT (nonselective adenosine 
blocker), prazosin (a1-blocker - 10IlM) & propranolol (~-blocker - 10J.tM) were 
administered, in separate experiments with or without metabolic 
preconditioning. 
Haemodynamic variables prior to and during ischaemia 
In control hearts antagonists were given 10 min prior to the index IIR. As 
shown in table 2, propranolol depressed the cardiac function but PZN and 
SPT did not have any effect to the cardiac function of control hearts prior the 
index I/R. In GLU(-) hearts antagonists were administered before, during and 
after GLU( -) period. The antagonists further depressed the cardiac function of 
GLU(-) hearts, an effect that was not reversed by glucose replenishment 
period, except for SPT. Administration of adenosine significantly depressed 
the cardiac function except when adenosine was given with SPT. The 
coronary flow (CF) was not affected by GLU(-) or antagonists perfusion but 


















Baseline Post treatment Pre-ischaemia TOC 
CF RPP CF RPP CF 
(mllmin) (10-3) (ml/min) (10-3) (ml/min) (min) 
CONT. 33.7 ±2.0 11.7 ± 1.2 33.7 ± 2.0 11.7 ± 1.2 10.0 ± 1.6 

GLU(-) 36.1 ± 2.6 12.5± 1.1 25.6 ± 1.9* 12.0 ± 1.4 32.4±2.2 10.8 ± 1.1 6.7 ±0.7 

CONT+PROP 36.2 ± 1.9 12.3 ± 0.8 21.7 ± 1.1* 11.2 ± 0.8 13.8 ±2.1 

GLU(-)PROP 30.9 ±2.0 12.4± 0.4 14.3 ± 1.5* 9.6± 0.7 14.6 ± 2.9* 10.0 ± 0.6 13.7±1.1 

CONT+PZN 35.4±0.9 13.0 ± 0.4 30.2 ± 2.7 9.8±0.6 11.2 ± 1.1 
GLU(-)PZN 34.3 ± 1.9 12.3 ± 0.7 17.0 ± 3.5* 7.2 ± 1.6 24.0 ±3.6 9.3 ± 1.0 5.2 ± 0.6.1\ 
CONT+SPT 38.6±2.0 14.0 ± 0.9 36.1 ±2.4 14.0 ± 0.9 11.2 ± 1.4 
GLU(-)SPT 38.3 ± 1.0 13.5 ± 0.6 23.8 ±2.6* 9.3± 1.1 31.8 ± 3.2 11.2 ± 1.1 5.8 ± 0.5.1\ 
CONT+ADO 37.9 ± 1.5 14.1 ± 0.6 22.8 ± 4.6* 18.1 ± 0.9* 22.8 ± 4.6* 18.1 ± 0.9* 9.4 ± 0.7 
ADO PC 32.7 ± 2.4 11.3 ± 1.1 19.1 ±4.8* 17.3 ± 1.4* 26.5±2.2 10.2 ± 0.8 8.3 ± 0.8 
ADO + SPT 31.5 ± 1.6 9.6 ± 0.4 30.9±2.8 13.8 ± 1.4* 29.5 ±2.0 9.5 ± 0.7 7.5±0.7 
Table 2 : Haemodynamic variables from cell surface receptor signalling substudy 
Baseline - at the end of stabilisation period; RPP - rate pressure product; CF - coronary flow; Post treatment - after 15 min 
GLU(-) and/or treatment with a pharmacological agent; Pre-ischaemia - before index ischaemia; TOe - time to onset of contra­
cture during ischaemia. CONT - glucose control; GLU(-) - glucose deprivation preconditioning; CONT+ PROPI PZNI SPTI ADO-
pretreatment with propranolol (PROP)I prazosin (PZN)/S-(-p-sulfophenyl) theophylline (SPT)I adenosine (ADO); GLU(-) PROPI 
PZN I SPT I ADO - pharmacological agents were given before, during and after GLU(-) before index ischaemia. ADO PC-
adenosine was administered as a preconditioning mimetic; ADO + SPT - adenosine preconditioning with adenosine receptor 












Post ischaemic contractile recovery 
When antagonists were administered as pretreatment, a and P - adrenergic 
receptor blockade significantly improved the post ischaemic contractile 
recovery of the control from (29.2 ± 3.4 %) to CaNT+PZN (45.5 ± 5.4 %) and 
CONT+PROP (56.2 ± 4.4 %), p < 0.05 vs control. This may have been due to 
decreased energy demand prior to ischaemia. Adenosine receptor blockade 
did not have any effect on the cardiac function of the controls, CaNT+SPT 
(22.3 ± 1.9 %), I\JS vs control. Of note, in these results antagonists were given 
for only 10 min instead of 30 min because in our pilot study the effect was the 
same, as to save pharmacological agents we only perfused for 10 min), 
figure 8{a). 
When antagonists were perfused with GLU(-), a and p -adrenergic receptor 
blockade did not have any additional protection on post ischaemic contractile 
function, GLU(-) (56.5 ± 1.0 %), GLU(-) PZN (50.2 ± 3.3 %) and GLU(-) PROP 
(55.5 ± 4.0 %). Adenosine blocker (SPT) significantly abolished GLU(-) 
protection from (56.5 ± 1.0 %) to GLU(-) SPT (36.7 ± 3.3 %), p < 0.01, figure 
8{b). To test the specificity of SPT in blocking adenosine, in our system, we 
perfused adenosine as PC mimetic (ADO PC). ADO PC conferred protection 
on post ischaemic contractile recovery, ADO PC (60.0 ± 6.9 %). 
The preconditioning like effect of adenosine was then blocked by SPT (28.4 ± 
2.6 %). When adenosine was given as a pretreatment it did not have any 
effects against index IIR (34.3 ± 5.5 %), figure 8{c). Collectively, these data 






































CO NT CO NT SPT CONTPZN CONTPROP 
TREATMENT 
Figure 8a The effects of adenosine, alpha and beta receptor blockade on post 
ischaemic contractile function when perfused as a pretreatment. Alpha blockade using 
prazosin (PZN) and beta blockade using propanolol (PROP) improved the post 
ischaemic contractile function when administered as a pretreatment whilst adenosine 
blockade using SPT did not have any effects. RPP (% of baseline) = rate pressure 
product at 30 min reperfusion. n ~ 6 at the end of reperfusion. All values are mean + 





























CONT GLU(-) GLUHPZN GLUHPROP GLU(-)SPT 
TREATMENT 
Figure 8b The effects of adenosine, alpha and beta receptor blockade on post 
ischaemic contractile function by SPT, prazosin and propanolol, respectively, in 
metabolically preconditioned hearts. RPP (% of baseline) = rate pressure product at 30 
min reperfusion. n ~ 6 at the end of reperfusion. All values mean + SEM. *p < 0.001 vs 































CaNT Pre ADO GLU(-) 
TREATMENT 
Figure Be The effects of adenosine when administered as a pretreatment or PC 
mimetic. Adenosine (ADO) mimicks GLU(-) protection and adenosine protection was 
abolished by adenosine receptor blocker (ADO + SPT). Adenosine pretreatment (Pre 
ADO) had no effect on the control. RPP (% of baseline) = rate pressure product at 30 
min reperfusion. 
All values mean + SEM, n 2: 6. *p < 0.05 vs control; #p < 0.05 vs ADO; NS vs control 













Post cell surface receptor blockade 
The activation of cell surface receptors leads to the activation of the 
downstream signalling events. These include the activation of protein kinase 
C and the subsequent opening of the mitochondrial KATP channels. We 
therefore determined whether protein kinase C and mitochondrial KATP 
channel were activated in metabolic preconditioning by using various 
pharmacological inhibitors. Post cell surface receptor blockade included the 
inhibition of PKC and blockade of the mito KATP channels. 
Haemodynamic variables prior to and during ischaemia. 
The protein kinase C inhibitor (chelerythrine) and the KATP channel blocker (5­
hydroxydecanoate) did not have any effects on the cardiac function and 
coronary flow of the control, IPC and GLU(-) hearts prior to the index IIR. 
During ischaemia, IPC and GLU(-) hearts, with or without antagonists, had an 
early onset of contracture and all the controls expectedly encountered a late 
onset. At 30rnin reperfusion all groups had a slight reduction in coronary flow 













Baseline Post treatment Pre-index ischaemia TOC 
RPP CF CF RPP CF 
(10.3) (ml/min) (ml/min) (10.3) (ml/min) (min) 
CONT 32.9 ± 1.0 
IPC 33.5 ± 1.5 
IPC + CHEL 33.3 ± 1.3 
IPC + SHD 34.1 ± 1.9 
GLU(-) 31.6±1.7 
CONT+CHEL 36.9 ± 1.5 
GLU(-)CHEL 35.7 ± 1.1 
CONT+SHD 36.9 ± 1.3 
GLU(-)SHD 34.6±2.3 
11.0 ± 0.9 32.9 ± 1.0 
11.7 ± 0.8 30.1±1.6 
12.0 ± 0.8 32.0 ± 0.9 
11.6 ± 0.7 30.5 ± 2.6 
11.5±0.7 17.4±1.4* 8.2±0.9 25.8±3.7 
12.7 ± 1.3 35.0 ± 1.6 
12.0 ± 0.2 26.2 ± 1.0 12.4 ± 0.3 31.5 ± 1.8 
12.0 ± 0.5 35.5 ± 2.3 
11.7±1.0 24.4±3.1 12.2±1.7 31.2±2.5 
11.0 ± 0.9 
12.0±1.1 
13.5 ± 1.0 
12.7 ± 0.4 
9.3±0.7 
13.0 ± 1.5 
11.9 ± 0.6 
12.0 ± 0.7 
11.2±1.5 
11.7 ± 0.5 
4.7 ± 0.4A 
5.3 ±0.4A 
6.8 ± 0.7A 
10.1 ± 1.2 
5.0 ±0.3A 
13.3 ± 1.0 
5.8 ± 0.3A 
Table 3 : Haemodynamic variables from the post receptor signalling substudy. 
Baseline· at the end of stabilisation period; RPP· rate pressure product; CF - coronary flow; Post treatment - after 15 min GLU(-) 
and/or treatment with a pharmacological agent; Pre-ischaemia· before index ischaemia; TOC - time to onset of contracture during 
ischaemia. CaNT· glucose control; GLU(·)· glucose deprivation preconditioning; IPC· ischaemic preconditioning; CONT+ CHEU 5HD 
pretreatment with chelerythrine (CHEL)I 5·hydroxydecanoate (5HD); IPC CHEL 15HD • pharmacological agents were administered 
before ischaemic preconditioning trigger IPC or GLU(·) CHEL 15HD - during and after GLU(·) before index ischaemia. 











Post ischaemic contractile recovery 
Protein kinase C antagonist, chelerythrine and mito KATP channel blocker, 5­
hydroxydecanoate did not have any significant effect on the post ischaemic 
contractile recovery of the controls, CONT (28.5 ± 2.8 %), CONT+CH EL (23.7 
± 3.8 %) and CONT+5HD (29.7 ± 2.6 %). As shown in figure 9, glucose 
deprivation protection, GLU(-) (59.8 ± 4.0 %), was abolished by PKC inhibitor 
GLU(-) CHEL (35.0 ± 4.8 %) and KATP channel blocker GLU(-) 5HD (23.8 ± 
3.4 %). p < 0.001. PKC inhibitor and KATP channel blocker also abolished 
protection afforded by ischaemic preconditioning, from IPC (56.7 ± 3.6 %) to 
IPC + CHEL (37.4 ± 1.1 %); IPC + 5HD (36.8 ± 3.8 %), p < 0.05. These 
results suggest that transient glucose deprivation protects against post 
ischaemic contractile dysfunction by activation of protein kinase C and 


































CONT PC PC PC 5HD GLU(-) GLU(-) GLU(-) 
CHEL CHEL 5HD 
TREATMENT 
Figure 9 The effects of protein kinase C and mitochondrial ATP sensitive potassium 
channel blockade on post ichaemic contractile function. PKC inhibitor, chelerythrine 
(CHEL) and potassium channel blocker (5HD) abolished ichaemic preconditioning and 
glucose deprivation preconditioning. RPP (% of baseline) =rate pressure product at 30 
min reperfusion. n > 6 at the end of reperfusion. All values mean + SEM. *p < 0.01 vs 











4.5 The role of protein kinase A inhibition in augmenting 
single episode of ischaemic preconditioning 
It has been shown that the levels of cAMP decline with the number of 
ischaemia I reperfusion episodes1, 2 and ischaemic preconditioning 
protection improves with the number of cycles3. Thus protein kinase A 
inhibition may contribute to improved post ischaemic contractile recovery after 
multiple episodes. We therefore compared single episode to multiple episodes 
of ischaemia and further investigated whether p-adrenergic induced protein 
kinase A activation during single episode of ischaemic preconditioning may 
limit this cardioprotection. In addition, we evaluated whether we could 
augment the cardioprotection afforded by single episode of ischaemic 
preconditioning by attenuating the activation of protein kinase A. 
Single episode versus multiple episodes of ischaemia 
After a period of 30 min ischaemia I reperfusion (index IIR), the control hearts 
(CONT) showed a significant reduction in post ischaemic contractile function 
compared to the baseline contractile function, CO NT (14.8 ± 3.0 %). Rat 
hearts preconditioned with single episode of 10 min global ischaemia 
improved post ischaemic contractile function, IPC 1 (45.0 ± 3.2 %) at the end 
of 30 min reperfusion. Rat hearts preconditioned with 3 x 5 min episodes of 
ischaemia, interspersed with 5 min reperfusion, before subjected to index I/R 
















that of single episode of ischaemic preconditioning, IPC 3 (62.8 ± 2.9 %) at 
the end of 30 min reperfusion, figure 10(a). 
This suggests that preconditioning with three episodes of ischaemia is better 
that one episode, but the exact mechanism underlying this phenomenon 
remains unclear. We therefore investigated whether a single episode of 
pharmacological preconditioning with an adenylate cyclase activator, forskolin 
and single episode of ischaemic preconditioning may be augmented by 
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Figure 10 (a) Three cycles of ischaemic preconditioning further improves post ischaemic contractile function compared to single episode of 
preconditioning. RPP (% of baseline) =rate pressure product at 5 min intervals during 30 min reperfusion. All values mean ± SEM; n.;:: 6 throughout. 












PKA inhibition on pharmacological preconditioning 
After a period of 30 min ischaemia I reperfusion, the control hearts (CONT) 
showed a significant reduction in post ischaemic contractile function 
compared to the baseline contractile function, CONT (17.3 ± 1.5 %). 
Ischaemic preconditioning (IPC 1) hearts were subjected to 10 min global 
ischaemia followed by 10 min reperfusion with a subsequent return of cardiac 
contractile function to the baseline level. Ischaemic preconditioning hearts 
showed significant improvement of the post ischaemic contractile recovery, 
IPC 1 (45.0 ± 3.2 %). To assess whether we could induce cardioprotection by 
transient activation of adenylate cyclase, an adenylate cyclase activator 
forskolin was used. Hearts were subjected to 5 min forskolin perfusion, an 
effect which significantly increased the cardiac function, followed by a 10 min 
drug-free perfusion with normal buffer, which returned the cardiac contractile 
function to baseline, before subjected to index ischaemia I reperfusion, 
(haemodynamic parameters prior to and during ischaemia) are shown in table 
4). We found that when forskolin was given as a preconditioning mimetic, it 
improved post ischaemic contractile function, FORSK (35.4 ± 0.9 %), NS vs 
IPC 1. Thus, forskolin preconditioning had a similar effect to a single episode 
of preconditioning, p<0.001 vs control. To determine protein kinase A's effect 
on forskolin preconditioning, we concurrently abrogated PKA activation with 
PKA inhibitor, H89 3min before and during 5 min forskolin period (see protocol 
figures). H89 significantly augmented the post ischaemic contractile recovery 
of forskolin preconditioning, FORSK+H89 (50.9 ± 3.9 %) p < 0.01 vs forskolin 
preconditioning, Figure 10(b). These data suggest that deleterious effect of 


















preconditioning; we therefore looked at the effect of abrogation of protein 













Baseline Post Treatment Pre - ischaemia TOC 
CF RPP CF CF 
(ml/min) (10.3) (ml/min) (mllmin) (min) 
CONT 33.8 ±2.9 11.6±0.7 33.8 ± 2.9 11.6 ± 0.7 10.3 ± 0.7 
IPC 34.4±2.1 12.4± 0.8 33.2 ±2.9 14.7 ± 0.7 4.80 ± 0.3/\ 
FORSKpc mimetic 34.7 ± 1.4 12.4±0.6 44.4 ±2.1* 15.7 ± 0.4* 32.0 ±2.3 10.8 ± 0.6 7.5 ± 0.4 
FORSK + H89 37.2 ±2.7 12.0 ± 0.5 46.2 ± 3.9 15.9 ± 0.2* 30.4 ± 1.9 10.7 ± 0.3 7.7 ± 0.5 
IPC + H89 34.0 ± 1.7 12.6 ± 0.7 35.0 ± 1.4 14.0 ± 0.6 41.0 ± 4.8 13.2 ± 0.6 6.10 ± 1.1/\ 
IPC + H89Rep. 33.9 ±2.1 12.7 ± 0.6 29.5± 1.9 12.0 ± 0.5 5.30 ± 0.8/\ 
H89pc mimetic 37.2 + 2.0 12.2 + 0.5 37.4 + 2.1 11.9 + 0.3 35.2 + 2.3 11.7 + 0.7 9.3 + 0.4 
H89Pretreatment 32.6 ± 3.0 13.2 ± 1.5 32.0 ± 2.0 14.0 ± 1.9 32.0 ± 2.0 14.0 ±1.9 11.0 ± 1.1 
Table 4: Heamodynamic variables from protein kinase A inhibition substudy 
Baseline at the end of stabilisation period; RPP - rate pressure product; CF - coronary flow; Post treatment after treatment with a 
pharmacological agent; Pre-ischaemia before index ischaemia; TOC - time to onset of contracture during ischaemia. CONT - control; 
IPC - ischaemic preconditioning; FORSKr>c mimetic - forskolin given as preconditioning mimetic; FORSK + H89 • forskolin PC with H89 
given before and during forskolin period; H89 was administered as a PC mimetic (H89 PC mimetic)' 3min prior to trigger ischaemia 
(IPC + H89) , 3min before index ischaemia (H89pre!rea!ment) , post trigger ischaemia before index ischaemia (IPC + H89Rep) 
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Figure 10 (b) Adenylate cyclase activator, forskolin, confers a preconditining like protection and PKA inhibitor(H89) further improves post ischaemic contractile 
function afforded by a single episode of forskolin preconditioning. RPP (% of baseline) =rate pressure product at 5 min intervals during 30 min reperfusion. All 











Protein kinase A inhibition on ischaemic preconditioning 
When H89 was perfused prior to the single episode of trigger ischaemia (IPC 
1 + H89) significant augmentation of post ischaemic contractile function was 
evident from the 5 min of reperfusion up to the end of the experiment. IPC 1 
(45.0 ± 4.3 %) vs IPC 1 + H89 (58.0 ± 2.8 %), p < 0.05 at the end of the 
experiment, figure10(c). 
When H89 was given as a pretreatment to index ischaemia, post ischaemic 
contractile function was also significantly improved from 20min reperfusion up 
to the end of the experiment - H89Pretreatment (37.0 ± 2.1 %), p<0.001 vs 
control. IPC 1 and CONT +H89 were not significantly different at all time points 
IPC 1(45.0 ± 4.3 %) vs H89Pretreatment (37.0 ± 2.1 %), NS. When H89 was 
administered as a PC mimetic the post ischaemic contractile recovery was not 
significantly different from the control - H89pc mimetic (15.4 ± 1.5 %) vs control 
(14.8 ± 3.0 %). This suggests that H89 itself does not precondition, 
figure10(d). 
When H89 was administered following the trigger ischaemia before index 
ischaemia - IPC 1 + H89Rep (36.6 ± 4.4 %), did not have any effect on the 
ischaemic preconditioning induced cardioprotection (47.6 ± 5.0 %), 
figure10(e). These data suggest that protein kinase A inhibition must be 
given prior to ischaemic preconditioning trigger to augment subthreshold 
ischaemic preconditioning effect or as a pretreatment against ischaemia I 
reperfusion insult to induce protection. 
Taken together, these data suggest that single episode of ischaemic 
preconditioning protects against prolonged ischaemia induced contractile 

















the protective effects of single episode of ischaemic preconditioning and that 
its inhibition prior to prolonged ischaemic insult improves post ischaemic 
contractile function. 
Having shown that PKA inhibitor, H89, was cardioprotective against 
ischaemia I reperfusion and augmented ischaemic preconditioning, to confirm 
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Figure 10 (c) A single episode of ischaemic preconditioning confers protection against ischaemia I reperfusion and PKA inhibitor(H89) further improves post. 
ischaemic contractile function afforded by a single episode of ischaemic preconditioning. RPP (% of baseline) = rate pressure product at 5 min inteNals during 
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Figure 10 (d) PKA inhibitor(H89) perfused as a pretreatment improves post ischaemic contractile function and did not any significant effects on the controls 
when given as a PC mimetic. RPP (% of baseline) = rate pressure product at 5 min intervals during 30 min reperfusion. All values mean ± SEM; 
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Figure 10 (e) A single episode of ischaemic preconditioning confers protection against ischaemia I reperfusion and PKA inhibitor(H89) perfusion following trigger 

ischaemia did not have any significant effect on post ischaemic contractile function afforded by a single episode of ischaemic preconditioning. RPP (% of 

baseline) =rate pressure product at 5 min intervals during 30 min reperfusion. All values mean ± SEM; n::: 6 throughout. 













Protein kinase A activity during trigger ischaemia of preconditioning 
In perfused hearts we have shown that protein kinase A inhibition protects 
against ischaemia-induced contractile dysfunction. Protein kinase A activity 
during 10 min acute myocardial ischaemia was therefore measured to 
correlate the inhibition of protein kinase A activity with augmentation of 
ischaemic preconditioning. In untreated hearts, the protein kinase A activity 
was significantly increased, baseline (1739 ± 190 pmol. min-1. mg protein-1) to 
end of 10 min trigger ischaemia (3055 ± 255 pmol. min-1. mg protein-\ 
p<0.001. Protein kinase A activity was unaffected during 3 min perfusion 
before ischaemia (1440 ± 255 pmol. min-1• mg protein-1 vs baseline, NS). 
When H89 was perfused 3 min prior to the ischaemic stimulus protein kinase 
A activity remained near to the baseline levels after 10 min ischaemia (1120 ± 
71 pmol. min-1. mg protein-1 vs baseline, NS), figure 10(f). The hearts that 
were subjected to ischaemic preconditioning protocol did not revert 
completely back to pre-IPC status following a significant ischaemic insult, 
however protein kinase A inhibition augmented ischaemic preconditioning 
induced cardioprotection suggesting that the trigger ischaemia of 
preconditioning comprises of two components, a protective component and a 
damaging component. The latter may be due to an increase in protein kinase 
A activity and subsequent Ca2 + influx during the trigger ischaemia of 
preconditioning. This may lead to limited ischaemic preconditioning 
cardioprotection. We therefore concluded that improved post ischaemic 
contractile function may have been due protein kinase A inhibition since we 






































Before trigger ischaemia end of trigger ischaemia 
Figure 10(f) Total activated cAMP dependent protein kinase (PKA) activity. In untreated hearts (black 
bars), PKA activity was significantly increased at the end of 10 min trigger ischaemia. In H89 treated 
hearts (white bars), PKA activity was significantly reduced to the baseline levels at the end of 10 min 


























The most important findings of this study are: 1) transient glucose deprivation 
induced protection on post ischaemic cardiac function appears to be through 
adenosine receptor activation, stimulation of the downstream signal protein 
kinase C (PKC) and subsequent opening of the mitochondrial ATP sensitive 
potassium (mito KATP) channels. 2) ischaemic preconditioning can be 
augmented by inhibiting protein kinase A activity during the trigger of 
preconditioning. 
5.1 Metabolic considerations and cardiac preconditioning 
Glucose serves as an important substrate for generation of energy in the 

heart. The heart utilises energy in the form of adenosine triphosphate (ATP). 

Under normal aerobic conditions the heart generates ATP from fatty acid and 

glucose metabolism and under ischaemic conditions glucose serves as the 

most important supply of energy. When oxygen is abundant, fatty acid 

metabolism produces more ATP than glucose, however, when oxygen is rate 

limiting more ATP is generated, mole per mole by glucose compared to fatty 

acids. Glycolysis is a catabolic process that converts glucose into pyruvate. 

Each molecule of glucose converted to pyruvate produces a net of 2 ATP4. 

When glucose is limiting, intracellular stores of glycogen serve as the source 





In the context of preconditioning the potential role that may be played by 













Inhibition of glycolysis and cardiac preconditioning 
Glycolysis is known to be inhibited by ischaemia, pyruvate or acetate54, 66, 
67, 2-Deoxyglucose (nonmetabolisable analogue of glucose)68, octanoate65, 
69, 70 and glucose depletion10. A brief exposure to some of the above 
metabolic perturbations has been shown to confer a preconditioning-like 
cardioprotection. The mechanism for this preconditioning-like cardioprotection 
is hypothesised to be through inhibition of glycolysis. 
In our study, transient inhibition of glycolysis .alone by a glycolytic inhibitor, 2­
Deoxyglucose, in the presence of glucose containing perfusate, produced no 
improvement of post ischaemic contractile function although glycolytic 
blockade appeared evident as demonstrated by a non-reversible depression 
of cardiac contractile function during and after administration of 2DG. 
Although we did not perfuse 2DG in the absence of glucose, a study by Wu71 
demonstrated that glucose depletion in the presence of 2DG still conferred 
cardioprotection in rat ventricular myocytes. We, therefore, perfused with 
pyruvate, a metabolic substrate known to indirectly inhibit glycolysis, in the 
absence of glucose. Pyruvate abolished glucose deprivation mediated 
protection. This may have been due to the ability of pyruvate to increase the 
cytosolic A TP above that of fatty acid fuels53 thereby increasing mitochondrial 
ATP levels72. This increase in mitochondrial ATP levels is may block 
mitochondrial ATP sensitive potassium channels hence the blockade of 
glucose deprivation preconditioning. Taken together, these data do not 
support a direct effect of glycolytic inhibition in the preconditioning-like 













Conversely, de Jonge28 found that short ischaemic episodes afford protection 
through enhanced glycolysis. ATP generated during anaerobic glycolysis 
protects sodium pump and the calcium uptake pump of the sarcoplasmic 
reticulum in ischaemic cells65. In addition, it has been suggested that 
glycolysis shutdown in ischaemic cells may have deleterious effects including 
acidosis73, ATP breakdown4, excess influx of calcium4, 49, accumulation of 
fatty acids74 and proton accumulation. However, the inhibited glycolysis 
during a preconditioning stimulus and during prolonged ischaemia may have 
different effects. 
The role of glycogen in cardiac preconditioning 
A role for glycogen in preconditioning is controversial. Some investigators 
have shown that glycogen depletion can be induced by brief periods of 
ischaemia 73, 75 by brief periods of anoxia73, following epinephrine 
infusion 76, pyruvate perfusion 77 and by glucose deprivation 1 ° confer 
ischaemic preconditioning-like cardioprotection. This cardioprotection through 
glycogen depletion is thought to be due to resultant reduction in lactate 
production and proton accumulation 78-80, via activation of Na+/H+ and 
Na+/Ca2+ exchange and by decreasingacidosis81 . In contrast, others have 
shown that protection against ischaemia requires glycogen availability73, 82­
88, whilst others suggest that glycogen depletion by itself is not effective 
enough in protecting against ischaemic injury89. 
In this study, we have shown that hearts subjected to transient glucose 















perfused hearts. As previously shown by our laboratory, earlier onset of 
ischaemia contracture is associated with glycogen depletion82. Thus as 
could be expected, our data suggest that the transient glucose depletion used 
prior to the index ischaemic insult accelerated glycogen depletion. However, 
as we did not measure glycogen levels in our study, we cannot directly 
evaluate or comment on what potential role glycogen depletion played in the 
glucose deprivation cardioprotection. 
Fatty acid metabolism I mobilisation and cardiac preconditioning 
Brief myocardial ischaemia stimulates moderate accumulation in fatty acids 
and severe cases of ischaemia lead to further increased accumulation of fatty 
acids74. Increased intracellular fatty acids during ischaemia may lead to 
imbalance of substrates and accumulation of unoxidised products of fatty 
acids90. High concentrations of fatty acids are said to disrupt cellular 
processes by causing non-specific detergent action on biomembranes74, 
inhibition of enzymes91 , uncoupling of oxidative phosphorylation in 
mitochondria92, stimulation of mitochondrial ATPase93 and development of 
ventricular arrhythmias in dogs94. 
Although fatty acid accumulation has detrimental effects on the heart, our 
laboratory has shown that uncoupling of the oxidative phosphorylation in 
mitochondria is one of the mechanisms by which ischaemic preconditioning 
manifests its cardioprotective effects95. In addition, fatty acid accumUlation 
inhibits glycolysis65, which, as previously mentioned, has been found to be 















mobilisation may be cardioprotective during transient period of glucose 
deprivation. To investigate the role of enhanced fatty acid mobilisation 
glucose perfused hearts were subjected to 15 min of excess medium chain 
fatty acid, octanoate, perfusion followed by fatty acid free period before 
subjected to index IIR. There was no loss of cardiac function during 
octanoate perfusion and there was no improved recovery. A combination of 
octanoate and glucose deprivation period had no effect or additional 
cardioprotective effect compared to glucose deprivation protection alone. This 
suggests that enhanced fatty acid mobilisation is not involved in the glucose 
deprivation protection. 
Following all the metabolic perturbation experiments, we concluded 
that the protective effect of glucose deprivation is not likely to be due to 
inhibition of glycolysis alone nor via fatty acid mobilisation. We therefore 
began to evaluate the possible cell Signalling pathways that may be activated 
by transient glucose deprivation. We postulated that one or more of these 
Signalling pathways might activate a preconditioning-like cardioprotective 













5.2 Cellular signalling and cardiac preconditioning 
Neuronal noradrenaline release and cardiac preconditioning 
Glucose deprivation is a metabolic stress and it may trigger the release of 
noradrenaline. Periods of ischaemia or anoxia are believed to result in the 
release of endogenous noradrenaline through nonexocytotic process from the 
neurons48,96. Noradrenaline release acts via a-adrenergic97 or p-adrenergic 
pathways2, 97. Transient activation of any of these two pathways has been 
shown to mimic ischaemic preconditioning2, 22, 47, 58, 97. In our model, 
glucose deprivation protection was unchanged by the administration of a­
adrenergic or p-adrenergic antagonists. 
In line with our findings, a-adrenergic blockade with prazosin59, 98 
phenoxybenzamine99 or bunazosin 100, when administered up to the onset of 
index I/R failed to prevent the protective effects of ischaemic preconditioning 
or transient p-adrenergic stimulation mediated preconditioning. Prazosin also 
failed to abolish ischaemic preconditioning effects98 even when washed out 
before index IIR59. In contrast with our findings prazosin attenuated the 
cardioprotective effects of preconditioning in dog 101, this may have been due 
to differences in species used. Additionally, pretreatment with a-adrenergic 
antagonists conferred cardioprotection in the ischaemia I reperfusion control 
hearts in our studies. In line with this, Nayler57 found that pretreatment with 
different concentrations of prazosin (1, 5 or 10IJM respectively) was protective 
against ischaemia I reperfusion insult. However, bunazosin or 


















On the other hand, glucose deprivation preconditioning was not affected by ~­
adrenergic blockade with propranolol, likewise, Yabe 102 found that ~­
adrenergic blockade with timolol failed to abolish ischaemic preconditioning 
when perfused up to the onset of index IIR but abolished isoproterenol 
preconditioning. When propranolol was administered as a pretreatment it was 
cardioprotective against ischaemia f reperfusion insult. Reimer103 also found 
that preatreatment with propranolol followed by coronary occlusion reduced 
necrosis in dogs. Contrary to this, pretreatment with ~-adrenergic blocker, 
timolol, did not have any cardioprotective effect against ischaemia f 
reperfusion insult. 
The cardioprotective effects of a-adrenergic or ~-adrenergic antagonists 
pretreatment may have been due to decreased energy demand or attenuated 
beta-adrenergic response59 or reduction in myocardial ischaemia f 
reperfusion induced Ca2 + overload prior to and f or during sustained 
ischaemia and during reperfusion 104. 
Despite the controversies that appear to hinder the unravelling of the 
exact mechanisms of a-adrenergic or ~-adrenergic signalling in 
preconditioning, we do not think that the failure of a-adrenergic or ~­
adrenergic blockade to abolish glucose deprivation preconditioning was due 
to administration of the antagonists up to the onset of index IfR. Moreover, 
due to the cardioprotective effect of a-adrenergic and ~-adrenergic 
antagonists observed in ischaemia f reperfusion control hearts, we cannot 
exclude a protective role of activated adrenergic receptor pathway during 











Adenosine production and cardiac preconditioning 
Adenosine is an important nucleoside known to have homeostatic and 
protective effects on the heart27. Ischaemia, anoxia or metabolic inhibition 
lead to the production of adenosine from ATP breakdown27, 105, 106. 
Transient adenosine administration has been shown to mimic ischaemic 
preconditioning through activation of adenosine (A1 and/or A3) receptor 
types105. Although both receptor types are involved in preconditioning A1 
receptor has been thoroughly investigated. Adenosine A1 receptor agonists, 
given as a trigger of ischaemia, confer cardioprotection against sustained 
ischaemia106, 107. 
This adenosine-induced cardioprotection may act in various ways. These 
include decreased catecholamine-induced metabolic and contractile 
responses 108, inhibition of norepinephrine release and/or reduction of 
intracellular calcium concentrations during ischaemia27 109, activation ofl 
PKC and subsequent opening of mito KATP channels via Gi protein 
activation27, 105, 110-112. 
In our study, we used glucose deprivation as a trigger of 
cardioprotection. Parallel to other studies, a non-selective adenosine receptor 
antagonist (SPT), abolished protection afforded by glucose deprivation. 
Although SPT is non-selective and cannot permeate the cell membrane we 
used sufficient dose (100J..lM) to block receptor activation (IC5o values for A1 
and A2 are 4.3J..lM and 6.2J..lM, respectively)55. To confirm this we 
preconditioned with adenosine and abolished the protective effects of 




















preconditioning has been abolished by adenosine receptor blockade9a, 
suggesting that metabolic and ischaemic preconditioning involves adenosine 
receptor activation. Contrary to our findings, Goto10 did not abolish 
protection induced by glucose deprivation with SPT. This finding may have 
been due to the different animal model and I or end-point used. In addition, 
Miura 105 argue that the extent of cardioprotection is mainly determined by 
interstitial adenosine levels achieved during ischaemic preconditioning and 
not by the level during sustained ischaemia. We therefore concluded that 
transient glucose deprivation leads to adenosine production, which as shown 
previously27, plays an important role in preconditioning-like cardioprotection. 
Role of protein kinase C in cardiac preconditioning 
One of the important downstream signalling events that has been found to be 
involved in cardioprotection against ischaemic injury is the activation of 
protein kinase C. Various cell surface G, - protein coupled receptors, 
including the a - adrenergic, adenosine and opioids facilitate the translocation 
of protein kinase C (PKC) from the cytosol to the sarcolemma29, 105. 
Translocation of protein kinase C results in the opening of the sarcolemmal 
and mitochondrial (KATP) channels60, 105 and activation of other kinases like 
tyrosine kinase and MAP kinases15. Protein kinase C agonists like phorbol 
myristate acetate or a diacylglycerol analogue have been shown to mimic 
ischaemic preconditioning32, 113, Although ischaemic preconditioning 
seems to be dependent on PKC translocation, not all isoforms of PKC elicit 


















or £ isoforms114-117. PKC a and £ are translocated to the plasma membrane 
and PKC 8 is translocated to the mitochondria30, 115 but some 
investigators 118, 119 believe that all three isoforms are translocated to the 
plasma membrane. Although, all of the three PKC isoforms are translocated 
by ischaemic preconditioning, PKC a rapidly dissociates from plasma 
membrane while PKC 8 and £ are retained for a long time 116. This evidence 
shows that PKC translocation as an important mediator of ischaemic 
preconditioning, we therefore looked at the role of PKC activation in the 
metabolic preconditioning model. 
In our study we have shown that a selective PKC antagonist, chelerythrine, 
(shown to inhibit all PKC isoforms) abolished glucose deprivation protection, 
suggesting that transient period of glucose inhibition lead to activation of PKC. 
Thus, in line with other PKC studies PKC activation has shown to be pivotal to 
the glucose deprivation cardioprotection 10, 71 and in ischaemic 
preconditioning29, 99. We therefore concluded that glucose deprivation 
protection acts, in part, via PKC activation. In our model, we did not delineate 
the putative isoforms activated, however we postulated that the PKC 8 and £ 
isoforms are involved. 
The likely end effector of cardiac preconditioning 
The activation of PKC and the resultant opening of the KATP channels has 
been considered as an important end-effector of ischaemic preconditioning. 
Moreover, it has been found that, pharmacological agents that block the 

















there are still uncertainty about the mechanism by which the opening of mito 
KATP channels confer cardioprotection, some consequences of mito K ATP 
channel opening have been suggested. These consequences include 
mitochondrial swelling, membrane depolarisation, perturbations in ATP 
synthesis, and in mitochondrial respiration35, 36. Interestingly, mitochondrial 
swelling is known to augment ATP production 37, this may be an adaptive 
mitochondrial response to cellular stress and/or to prevent Ca2 + overload36. 
These may be the mechanisms by ischaemic preconditioning confer 
cardioprotection against ischaemic insult. 
In this study we looked at the possible role of mito K ATP channel in 
glucose deprivation protection. We found that glucose deprivation protection 
was abolished by mito K ATP channel inhibitor, 5-hydroxydecanoate. This is 
parallel to the findings that opening of mito KATP channels is involved in the 
mechanism by which preconditioning affords cardioprotection25, 38, 52, 120. 
According to our knowledge there is no work that has linked glucose 
deprivation preconditioning to the opening of mito KATP channels. 
Other studies have linked ischaemic preconditioning cardioprotection to 
adenosine receptor activation, protein kinase C activation and subsequent 
opening of mito KATP channels. We therefore conclude that transient glucose 
deprivation mimics ischaemic preconditioning through adenosine receptor 












5.3 Augmented preconditioning by inhibition of protein kinase 
A activity_ 
Involvement of l3-adrenergic receptor pathway in cardiac 
preconditioning 
The trigger ischaemia of preconditioning has been shown to protect the 
isolated rat heart against post-ischaemic contractile dysfunction 18, 52. As 
previously shown in this study, one mechanism of ischaernic preconditioning 
involve the activation of protein kinase C and opening of the mitochondrial 
ATP-sensitive potassium channels. On the other hand, it is believed that 
periods of ischaemia or anoxia lead to stimulation of l3-adrenergic pathways2, 
97, 121 and subsequent accumulation of Ca2+ 122. Other studies have shown 
that transient l3-adrenergic stimulation protects against prolonged ischaernia2, 
97, 100. Other studies showed that transient l3-adrenergic stimulation 
cardioprotection induces protein kinase C activation via an increase in the 
intracellular Ca2+ concentration19, 102. Moreover, Strasser56 showed that 
independent activation of protein kinase C during short ischaemic episode 
stimulates adenylate cyclase, this activation occurred rapidly after the onset of 
ischaemia (5-15 minutes), therefore suggesting possible involvement of 
adenylate cyclase activation in cardioprotection. In this study we have shown 
that transient activation of adenylate cyclase, shown to increase the cAMP 
levels2, 56, conferred a preconditioning-like cardioprotection. Suggesting a 
possible involvement of j3-adrenergic receptor induced activation of adenylate 
cyclase during ischaemic preconditioning trigger as a mechanism whereby 
ischaemic preconditioning affords cardioprotection. However, Sandhu1 
92 

~· r er i















showed that decrease in adenyl ate cyclase activation and subsequent 
increase in cAMP levels during sustained ischaemic insult following three 
ischaemic episodes did not account for protection against myocardial 
infarction. 
In contrast, other studies have shown that transient attenuation of p­
adrenergic receptor activation preconditions the heart against sustained 
ischaemia59. In support of this concept, it is believed that adenosine 
released27, 109, activation of G-inhibitory protein by opioids25, 71, 123, 124 
during ischaemic trigger of preconditioning protects the heart by attenuating 
the adverse effects of p-adrenergic receptor stimulation. 
Although there is a controversy about the possible involvement p-adrenergic 
pathway stimulation, we have found that transient activation of adenylate 
cyclase by forskolin protects the isolated rat hearts against ischaemia / 
reperfusion insult. This controversy does not bring into the picture the 
possible role of protein kinase A activation during ischaemic preconditioning. 
Secondly we observed that the mechanical function of the hearts subjected to 
ischaemic preconditioning did not revert completely back to baseline 
mechanical function following the index ischaemic insult, hence there is still 
room for further protection of these hearts. 
The possible role of protein kinase A in cardiac preconditioning 
Myocardial ischaemia and pharmacological activation of adenylate cyclase 
lead to an increase in the cAMP levels56 and the activation the cAMP 
dependent protein kinase (PKA)4. However, the levels of cAMP decline with 














preconditioning protection improves with the number of cycles3. Thus protein 
kinase A inhibition may contribute to improved post ischaemic contractile 
recovery after multiple episodes. In this study, we looked at the effects of 
concurrent inhibition of protein kinase A activation in both ischaemic and 
pharmacologically induced preconditioning. In this study, when H89 (PKA 
inhibitor) was perfused concurrently with adenylate cyclase activator (forskolin 
preconditioning) it augmented the functional recovery achieved with forskolin 
preconditioning. We therefore perfused H89 prior to the trigger of ischaemic 
preconditioning. Again, H89 augmented ischaemic preconditioning and when 
H89 was perfused as a pre-treatment it protected the same way as ischaemic 
preconditioning. From the protein kinase A activity data, this was found to be 
due to reduced protein kinase A activity during ischaemic trigger of 
preconditioning. Although the mechanisms through which inhibition of protein 
kinase A activity protects is not known exactly, we hypothesised that 
cardioprotection may be due to an inactivation of L-type Ca2 + channels and 
subsequent decrease in ischaemia-induced cytosolic free Ca2+ accumulation. 
In line with our findings, Steenbergen 122 showed that there is an elevation of 
cytosolic free calcium concentration early in myocardial ischaemia, moreover, 
Miyawaki19 showed that transient Ca2 + depletion followed by Ca2 + 
replenishment protects against ischaemic injury, this may therefore account 
for the damaging component of preconditioning ischaemia. 
We demonstrated that three episodes of ischaemic preconditioning 
elicited greater post ischaemic contractile recovery than one cycle and that 
the protective effects of sublethal ischaemic and/or pharmacological 











augmented by protein kinase A inhibition. We therefore conclude that 
increased PKA activity during the sublethal episode of preconditioning may 
limit the post ischaemic contractile recovery. Although we conclude that 
ischaemic preconditioning induced protection can be further augmented by 
blocking the PKA activation, it is important to mention that ~-adrenergic 
signalling cascade is an essential trigger of ischaemic preconditioning since 
we have shown that adenylate cyclase activator, forskolin, preconditions and 



























We have found that transient glucose deprivation preconditions the heart 
through adenosine receptor induced protein kinase C activation and 
subsequent opening of the mitochondrial ATP sensitive potassium channel. 
However, protein kinase C activation during transient glucose deprivation is 
unlikely to be mediated via a1 I p- adrenergic receptor activation. In addition, 
inhibition of protein kinase A activity further enhances the protective effects of 
subthreshold episode of preconditioning on post ischaemic contractile 
function. Suggesting that the trigger ischaemia of preconditioning may be 
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7. IMPLICATIONS AND UNANSWERED QUESTIONS 
In the first part of this study we looked at the effect of transient glucose 
deprivation on post ischaemic contractile function. During glucose deprivation 
period and during administration of U1 and ~ blockers (prazosin and 
propranolol, respectively) the contractile function dropped significantly (see 
tables 1-3). Decrease in cardiac function may lead to decrease in energy 
demands leading to protection against myocardial infarction 125, amelioration 
of left ventricular dysfunction 126-128 and protection against ischaemia 
induced arrhythmias and fibrillation 129. We do not know if this decrease in 
contractile function played any significant role in cardioprotection. 
In GLU(-) hearts prazosin and propranolol was given up to the onset of 
index IIR because some investigators predict that the protective effects of 
preconditioning stimulus/ stimuli like activation of PKC 116 and subsequent 
activation of MAP kinases 130 and tyrosine kinase 131, 132 remain activated 
after preconditioning stimuli and probably carried up to the index ischaemia 
where they effect protection. Kawamura 116 showed that PKC 0 and E (PKC 
isoforms regarded as key role players in preconditioning) are still highly 
activated 10 min later after preconditioning stimulus hence it is important to 
block PKC after preconditioning stimulus32. To prevent any possible alpha 
and/or beta adrenergic induced activation of PKC, MAP kinases and / or 
tyrosine kinase during the washout period we administered antagonists up to 














Concerning the concentration of prazosin: Nayler57, showed that different 
concentrations of prazosin (1, 5 & 10 11M) were protective against index I/R 
and found 111M prazosin to be optimal but the same concentration failed to 
abolish ischaemic preconditioning protection59. Additionally, they showed that 
90 min perfusion with different concentrations of prazosin (1, 5 & 10 11M) did 
not have any significant differences on ATP, CP and Ca2 + levels. We 
therefore think that concentration used in this study was probably sufficient to 
block alpha receptor activation. 
Possible activation by jJ-adrenergic receptor activation and its effectcs 
on cardioprotection - it has been shown that ~-adrenergic receptor 
activation may lead to activation of PKC via transient elevation of Ca2 +. 
Transient ~-adrenergic receptor activation by isoproterenol led to translocation 
of PKC 0 from the cytosol to membrane fraction (marker of PKC 
activation)102. Moreover, Miyawaki133 showed that isoproterenol 
preconditioning led to transient elevation of Ca2 + and subsequent activation of 
PKC. Additionally, they showed that ~-adrenergic receptor blocker, 
propranolol, and PKC inhibitor, chelerythrine, completely abolished 
cardioprotective effects of isoproterenol preconditioning. Therefore the aim 
of the study was to block any possible ~-adrenergic receptor-induced 

















PKA inhibition substudy - In the second part of our study we found that 
pharmacological preconditioning with adenylate cyclase activator, forskolin 
improves left ventricular contractile dysfunction. During forskolin perfusion 
there was a significant increase in the contractile function (both heart rate and 
the developed pressure). Some investigators have shown that a transient 
increase in cardiac function confers cardioprotection. Cell stretching or acute 
volume overload134 and rapid cardiac pacing135, 136, bypassing p 
adrenergic pathway stimulation, have been shown to protect the heart against 
ischaemic injury and myocardial infarction. We do not know whether forskolin 
preconditioning was due to p adrenergic pathway stimulation alone or merely 
due to increased heart rate and I or developed pressure. 
Specificity ofprotein kinase A inhibitor, H89 
The evidence for protein kinase A inhibition by H89 was provided by direct 
measurements of protein kinase A activity {Figure 10{d)}. However, the 
concentration of 2/-IM H89 used in this study may also inhibit cGMP protein 
kinase G {PKG)62. The possible involvement of PKG in this study is unlikely 
due to the fact that cyclic GMP and cGMP kinase have been shown to elicit 
protective effects 137, 138. Inhibition of PKG would hypothetically lessen 
rather than augmenting ischaemic preconditioning protection. In addition, a 
closely related protein kinase A inhibitor; H-8 which is 30 times less potent 
than H89, has been shown to reduce the incidence of torsdes de pOintes in 
rabbits139, yet H89 inhibits PKG 10 times less62. We therefore conclude that 
our data relate to predominant inhibition of protein kinase A. 
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8. FUTURE DIRECTIONS 
Glucose deprivation and metabolic pathways 
In the first part of our study we looked at metabolic versus signalling events 
happening during glucose deprivation. In metabolism study we did not 
measure glycogen levels, rates of glycolysis nor rates of fatty acid oxidation. 
All these metabolic events may have played a significant role in glucose 
deprivation protection. We therefore aim to measure glycogen levels, rates of 
glycolysis and rates of fatty acid oxidation to get insight into these metabolic 
consequences. 
Endpoint of ischaemic preconditioning 
The end-point of ischaemic preconditioning used in this study is post 
ischaemic contractile dysfunction. Although post ischaemic contractile 
function is now considered as an alternate end point (because it is likely be a 
mixture of stunning, hibernation and apoptosis I necrosis). Investigators do, 
however, use ischaemic preconditioning to improve post ischaemic contractile 
dysfunction2, 18, 52. Several end-points are accepted, yet the measurement 
of infarct size remains the gold standard in both in vitro and in vivo 
models140. Additionally, as opposed to contractile dysfunction ~ adrenergic 
pathway may not play role in infarct size reduction 1. As cell survival is the 
paramount endpoint we plan to use molecular manipulations in vitro to 
investigate the regulation of protein kinase A in cardiomyocytes or skeletal 
muscles (C2C12) cells in the context of preconditioning. Further studies are 
necessary to investigate the role of protein kinase A inhibition in reducing 











kinase A inhibition augmented ischaemic preconditioning by further reducing 
stunning / hibernation and decreasing apoptosis I necrosis. 
Cyclic AMP I protein kinase A measurements 
We have already shown that H89 inhibits protein kinase A activity during 
ischaemic preconditioning trigger and that augments preconditioning. To 
further il1vestigate the harmful effect of index ischaemia that limits 
preconditioning, we plan to maximally activate cAMP / PKA with adenylate 
cyclase activator, forskolin and then measure the levels of cAMP during 
ischaemic trigger of preconditioning. Additionally, we are going to measure 
both cAMP levels and protein kinase A activity at the end of index ischaemia 
and compare untreated hearts and H89 treated hearts. This will allow us to 
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